Live from the NIH registry
Studies recruiting near Salinas right now
Top 25 of 49 recruiting studies, sorted by proximity — each links to its official registry page
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Phase 3
Interventional 880 participants sought
Dominican Santa Cruz Hospital — Santa Cruz, California (29.6 mi)
· Sponsor: NRG Oncology
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Renal Pelvis and Ureter Urothelial Carcinoma
Phase 2, Phase 3
Interventional 131 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Phase 2, Phase 3
Interventional 189 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast Cancer, Early Breast Cancer
Phase 3
Interventional 5,500 participants sought
Research Site — Monterey, California (15.8 mi)
· Sponsor: AstraZeneca
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Arrhythmia, Bradycardia
N/A
Observational 20,000 participants sought
Research site — Salinas, California (1.5 mi)
· Sponsor: Medtronic
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Lymphoma, Non-Hodgkin, Multiple Myeloma
Phase 2
Interventional 4,200 participants sought
Sutter Palo Alto Medical Foundation: Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: American Society of Clinical Oncology
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
COPD (Chronic Obstructive Pulmonary Disease)
Phase 3
Interventional 5,250 participants sought
Research Site — Castroville, California (8.8 mi)
· Sponsor: AstraZeneca
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 1,524 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Diabetic Kidney Disease (DKD)
Phase 2
Interventional 195 participants sought
Central Coast Nephrology — Salinas, California (1.5 mi)
· Sponsor: Regeneron Pharmaceuticals
E-Mindfulness Approaches for Living After Breast Cancer
Breast Cancer, Depression
Phase 3
Interventional 402 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: NRG Oncology
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Multiple Myeloma
Phase 1
Interventional 134 participants sought
Pacific Cancer Care — Monterey, California (15.8 mi)
· Sponsor: Oncotherapeutics
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
N/A
Interventional 535 participants sought
Dominican Santa Cruz Hospital — Santa Cruz, California (29.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings
Anxiety, Mood Disorders
N/A
Interventional 156 participants sought
Ohana Center for Child and Adolescent Behavioral Health — Monterey, California (15.8 mi)
· Sponsor: Stanford University
Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)
Middle Schools, School Exclusion
N/A
Interventional 5,076 participants sought
Soquel Union Elementary School District — Capitola, California (26.6 mi)
· Sponsor: University of Oregon
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Phase 3
Interventional 1,450 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Phase 2
Interventional 124 participants sought
Dominican Santa Cruz Hospital — Santa Cruz, California (29.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Product Surveillance Registry
Cardiac Rhythm Disorders, Urological Disorders
N/A
Observational 100,000 participants sought
Research site — Salinas, California (1.5 mi)
· Sponsor: Medtronic
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Multiple conditions
N/A
Observational 2,900 participants sought
Dominican Santa Cruz Hospital — Santa Cruz, California (29.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Phase 3
Interventional 4,220 participants sought
Pacific Cancer Care - Oncology — Monterey, California (15.8 mi)
· Sponsor: Stemline Therapeutics, Inc.
Toddlers' Responses to Strangers
Social Behavior
N/A
Observational 100 participants sought
Social Science 2 Building — Santa Cruz, California (29.6 mi)
· Sponsor: University of California Santa Cruz
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
Phase 2, Phase 3
Interventional 1,912 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: NRG Oncology
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 2
Interventional 56 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: SWOG Cancer Research Network